Eli Lilly defeats billion-dollar claim over trade secrets
The parties collaborated to develop rapid-action insulin to treat diabetes (Credit: iStock/mcbrugg)
US pharmaceutical group Eli Lilly & Company has defeated a US$1.8 billion claim by a French biotech company that alleged it had misused trade secrets and confidential information.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Subscribe now